市場調查報告書
商品編碼
1426971
手術止血劑市場,按產品類型(局部凝血酶基、流動性、膠原基、氧化再生纖維素基、明膠基和組合)、配方(基質、海綿、粉末)、應用、最終用途 - 全球預測(2024 -2032)Surgical Hemostats Market, By Product Type (Topical Thrombin-Based, Flowable, Collagen-Based, Oxidized Regenerated Cellulose-Based, Gelatin-Based, & Combination), Formulation (Matrix, Sponge, Powder), Application, End-use -Global Forecast (2024-2032) |
在減少術後併發症的共同努力的推動下,2024 年至 2032 年,手術止血劑市場規模預計將以 5.6% 的CAGR擴大。
最近,外科醫生正在優先考慮有效的止血解決方案來控制手術過程中和手術後的出血,以降低併發症的風險並改善患者的預後。醫療保健專業人員越來越重視患者的安全和康復,從而大量採用先進的止血劑。創新止血技術的不斷發展旨在提高功效並最大限度地減少不良反應,這將推動產品的採用。此外,止血劑的持續創新,包括開發先進材料和配方以提高功效和適用性,將有助於產業成長。例如,2023年11月,Ethicon宣布批准ETHIZIATM,這是一種經過臨床認證的補充止血解決方案,用於在難以控制出血的情況下維持止血。
該行業分為產品類型、配方、應用、最終用途和地區。
根據產品類型,預計 2024 年至 2032 年間,膠原蛋白手術止血劑市場的CAGR將達到5.2%。這是由於膠原蛋白產品因其多功能性和有效控制出血的能力而受到越來越多的青睞。手術止血劑在各種手術應用中具有止血功效、生物相容性和易用性。此外,膠原蛋白的天然止血特性使其在各種手術中的應用激增,包括骨科、心血管和牙科手術。此外,提高膠原蛋白止血劑性能和適用性的技術進步將推動該領域的成長。
就最終用途而言,到 2032 年,門診手術中心領域的手術止血劑行業預計將實現 5.4% 的成長率。患者對門診手術中心 (ASC) 醫療治療的日益偏好可歸因於其效率、成本-有效性和微創手術。在門診環境中進行的各種外科手術中,對有效控制出血的需求不斷成長,也刺激了產品需求。
由於外科手術的增加、醫療保健基礎設施的增加以及對先進醫療產品的認知不斷增強,亞太地區手術止血劑產業預計在 2024 年至 2032 年期間將呈現 6% 的成長率。慢性病和擇期手術的盛行率激增,導致對高效止血解決方案的需求更高。此外,政府促進醫療保健發展的舉措,加上手術技術的不斷進步以及對盡量減少術後併發症的高度重視,將加速區域產業的擴張。
Surgical Hemostats Market size is poised to expand at 5.6% CAGR from 2024 to 2032 driven by the concerted efforts to minimize postoperative complications.
Of late, surgeons are prioritizing effective hemostatic solutions to control bleeding during and after surgical procedures for reducing the risk of complications and improving patient outcomes. Healthcare professionals are increasingly emphasizing patient safety and recovery, surging the adoption of advanced hemostatic agents. The continuous development of innovative hemostatic technologies, aimed at enhancing efficacy and minimizing adverse effects will fuel the product adoption. Furthermore, the ongoing innovations in hemostatic agents, including the development of advanced materials and formulations to improve efficacy and applicability will contribute to the industry growth. For instance, in November 2023, Ethicon announced the approval of ETHIZIATM, a clinically certified supplementary hemostat solution to maintain hemostasis in circumstances of difficult-to-control bleeding.
The industry is segmented into product type, formulation, application, end-use, and region.
Based on product type, the collagen-based surgical hemostats market is projected to witness 5.2% CAGR between 2024 and 2032. This is owing to the increasing preference for collagen-based products for their versatility and ability to control bleeding effectively. Surgical hemostats provide hemostatic efficacy, biocompatibility, and ease of use in various surgical applications. Additionally, the natural hemostatic properties of collagen are surging its use for diverse surgeries, including orthopedic, cardiovascular, and dental procedures. Furthermore, technological advancements to enhance the performance and applicability of collagen-based hemostats will propel the segment growth.
In terms of end-use, the surgical hemostats industry from the ambulatory surgical centers segment is expected to record 5.4% growth rate through 2032. The growing patient preference for medical treatments at ambulatory surgical centers (ASCs) can be attributed to their efficiency, cost-effectiveness, and minimally invasive procedures. The rising need for effective bleeding control in diverse surgical interventions performed in outpatient settings is also fueling the product demand.
Asia Pacific surgical hemostats industry is set to exhibit 6% growth rate during 2024-2032 attributed to the rising surgical procedures, increasing healthcare infrastructure, and the growing awareness about advanced medical products. The surging prevalence of chronic diseases and elective surgeries is contributing to the higher demand for efficient hemostatic solutions. Moreover, government initiatives for promoting healthcare development coupled with the ongoing advancements in surgical techniques and the strong focus on minimizing postoperative complications will accelerate the regional industry expansion.